Literature DB >> 9150391

Inactivation of p53 results in high rates of homologous recombination.

K L Mekeel1, W Tang, L A Kachnic, C M Luo, J S DeFrank, S N Powell.   

Abstract

Using a plasmid substrate which integrates into the genome, we determined that the rate of homologous recombination was suppressed by p53. Human tumor cell lines, mutant or null for p53 had recombination rates 10000-times greater than primary fibroblasts. When isogenic cell pairs from tumor cells or primary fibroblasts were compared, differing only in one genetic change which inactivated p53, the recombination rate increased > 100-fold. Functional inactivation of p53 by dominant mutant p53, by large T antigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the same result. Our results suggest that p53 suppresses spontaneous homologous recombination, and that p53 is not required for recombination to proceed. The mechanism of recombination suppression may be related to the reported association of p53 with Rad 51, but the functional consequences of this association are not yet established. It is suggested that suppression of homologous recombination is the means by which p53 maintains genetic stability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150391     DOI: 10.1038/sj.onc.1201143

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core.

Authors:  S B Zotchev; M Protopopova; G Selivanova
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

Review 2.  Manipulating the mammalian genome by homologous recombination.

Authors:  K M Vasquez; K Marburger; Z Intody; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

3.  Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining.

Authors:  F Xia; D G Taghian; J S DeFrank; Z C Zeng; H Willers; G Iliakis; S N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase.

Authors:  Christian Melle; Heinz-Peter Nasheuer
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

5.  A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway.

Authors:  Y Saintigny; A Dumay; S Lambert; B S Lopez
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

6.  Possible anti-recombinogenic role of Bloom's syndrome helicase in double-strand break processing.

Authors:  Rosine Onclercq-Delic; Patrick Calsou; Christine Delteil; Bernard Salles; Dora Papadopoulo; Mounira Amor-Guéret
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

7.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.

Authors:  Sridharan Rajagopalan; Antonina Andreeva; Trevor J Rutherford; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

9.  Discriminatory suppression of homologous recombination by p53.

Authors:  Sheng Yun; Chadwick Lie-A-Cheong; Andrew C G Porter
Journal:  Nucleic Acids Res       Date:  2004-12-15       Impact factor: 16.971

10.  DNA substrate dependence of p53-mediated regulation of double-strand break repair.

Authors:  Nuray Akyüz; Gisa S Boehden; Silke Süsse; Andreas Rimek; Ute Preuss; Karl-Heinz Scheidtmann; Lisa Wiesmüller
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.